Skip to main content

Table 2 Performance of the biomarkers for the diagnosis of cholangiocarcinoma

From: Detection of serum MMP-7 and MMP-9 in cholangiocarcinoma patients: evaluation of diagnostic accuracy

Biomarker (cut-off value) Sensitivity (%) (95% CI) Specificity (%) (95% CI) PLR (95% CI) NLR (95% CI)
CEA
(3 ng/ml)
70.73
(55.52–82.39)
43.75
(28.17–60.67)
1.26
(0.87–1.81)
0.67
(0.36–1.24)
CEA
(5 ng/ml)
58.54
(43.37–72.24)
62.50
(45.25–77.07)
1.56
(0.93–2.62)
0.66
(0.42–1.04)
CA19-9
(35 U/ml)
81.82
(68.04–90.49)
48.48
(32.50–64.78)
1.59
(1.11–2.27)
0.38
(0.18–0.77)
CA19-9
(100 U/ml)
70.45
(55.78 – 81.84)
63.64
(46.62–77.81)
1.94
(1.19–3.16)
0.46
(0.28–0.78)
MMP-9
(15.0 ng/ml)
63.64
(48.87–76.22)
41.94
(26.42–59.23)
1.67
(0.93–3.01)
0.59
(0.35–0.98)
MMP-9
(20.0 ng/ml)
34.10
(21.88–48.86)
74.19
(56.75–86.30)
1.32
(0.64–2.73)
0.89
(0.66–1.20)
MMP-7
(6.0 ng/ml)
76.32
(60.79–87.01)
46.88
(30.87–63.55)
1.44
(0.99–2.08)
0.51
(0.26–1.00)
MMP-7
(7.4 ng/ml)
63.16
(47.28–76.62)
71.88
(54.63–84.44)
2.25
(1.23–4.11)
0.51
(0.32–0.82)
  1. The sensitivity, specificity, positive and negative likelihood ratio (LR) as well as their 95% confidence interval (CI) for each marker is presented. The likelihood ratio is the ratio of true and false positives (sensitivity and 1-specificity respectively), where the higher values reflect the probability of a better performance. (PLR, positive likelihood ratio; NLR, negative likelihood ratio; 95% CI, 95% confidence interval)